81 related articles for article (PubMed ID: 16805966)
1. Ursodeoxycholic acid in primary biliary cirrhosis improves glutathione status but fails to reduce lipid peroxidation.
Pemberton PW; Aboutwerat A; Smith A; Warnes TW
Redox Rep; 2006; 11(3):117-23. PubMed ID: 16805966
[TBL] [Abstract][Full Text] [Related]
2. Oxidant stress is a significant feature of primary biliary cirrhosis.
Aboutwerat A; Pemberton PW; Smith A; Burrows PC; McMahon RF; Jain SK; Warnes TW
Biochim Biophys Acta; 2003 Mar; 1637(2):142-50. PubMed ID: 12633902
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group.
Poupon RE; Huet PM; Poupon R; Bonnand AM; Nhieu JT; Zafrani ES
Hepatology; 1996 Nov; 24(5):1098-103. PubMed ID: 8903382
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive monitoring of oxidant stress in alcoholic liver disease.
Pemberton PW; Smith A; Warnes TW
Scand J Gastroenterol; 2005 Sep; 40(9):1102-8. PubMed ID: 16165720
[TBL] [Abstract][Full Text] [Related]
5. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.
Matsuzaki Y; Tanaka N; Osuga T; Aikawa T; Shoda J; Doi M; Nakano M
Am J Gastroenterol; 1990 Jan; 85(1):15-23. PubMed ID: 1967512
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress.
Serviddio G; Pereda J; Pallardó FV; Carretero J; Borras C; Cutrin J; Vendemiale G; Poli G; Viña J; Sastre J
Hepatology; 2004 Mar; 39(3):711-20. PubMed ID: 14999689
[TBL] [Abstract][Full Text] [Related]
7. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
[TBL] [Abstract][Full Text] [Related]
8. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
9. Enhanced hepatic Nrf2 activation after ursodeoxycholic acid treatment in patients with primary biliary cirrhosis.
Kawata K; Kobayashi Y; Souda K; Kawamura K; Sumiyoshi S; Takahashi Y; Noritake H; Watanabe S; Suehiro T; Nakamura H
Antioxid Redox Signal; 2010 Aug; 13(3):259-68. PubMed ID: 20055754
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid enhances fractional calcium absorption in primary biliary cirrhosis.
Verma A; Maxwell JD; Ang L; Davis T; Hodges S; Northfield TC; Zaidi M; Pazianas M
Osteoporos Int; 2002 Aug; 13(8):677-82. PubMed ID: 12181628
[TBL] [Abstract][Full Text] [Related]
12. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
[TBL] [Abstract][Full Text] [Related]
14. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
[TBL] [Abstract][Full Text] [Related]
15. Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis.
Lukivskaya O; Zavodnik L; Knas M; Buko V
Adv Med Sci; 2006; 51():54-9. PubMed ID: 17357278
[TBL] [Abstract][Full Text] [Related]
16. Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis.
Yang YY; Huang YT; Lee KC; Lee FY; Lee TY; Hou MC; Lin HC; Lee SD
Clin Sci (Lond); 2009 Jan; 116(1):71-9. PubMed ID: 18479249
[TBL] [Abstract][Full Text] [Related]
17. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid.
Stojakovic T; Putz-Bankuti C; Fauler G; Scharnagl H; Wagner M; Stadlbauer V; Gurakuqi G; Stauber RE; März W; Trauner M
Hepatology; 2007 Sep; 46(3):776-84. PubMed ID: 17668874
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
20. Prolonged treatment with ursodeoxycholic acid for primary biliary cirrhosis.
Crippa G; Cagnoni C; Castelli A; Concesi C; Girometta S; Pancotti D; Sverzellati E; Tacchini G; Pierfranceschi MG; Carrara GC
Clin Ter; 1995 May; 146(5):367-72. PubMed ID: 7796569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
